Jefferies Financial Group Inc. Takes $15.44 Million Position in Castle Biosciences, Inc. $CSTL

Jefferies Financial Group Inc. acquired a new position in Castle Biosciences, Inc. (NASDAQ:CSTL) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 647,391 shares of the company’s stock, valued at approximately $15,440,000.

Several other institutional investors have also recently made changes to their positions in CSTL. Amundi raised its stake in Castle Biosciences by 15,811.5% during the 1st quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after purchasing an additional 4,111 shares during the period. AQR Capital Management LLC boosted its stake in Castle Biosciences by 548.9% in the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after purchasing an additional 115,907 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Castle Biosciences by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after buying an additional 655 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in Castle Biosciences by 10,592.0% during the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after buying an additional 2,648 shares in the last quarter. Finally, Legal & General Group Plc raised its position in shares of Castle Biosciences by 34.7% during the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock valued at $713,000 after buying an additional 8,992 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on CSTL shares. Robert W. Baird set a $36.00 target price on shares of Castle Biosciences in a report on Friday, July 31st. Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Wall Street Zen upgraded shares of Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, KeyCorp set a $35.00 price objective on shares of Castle Biosciences in a report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Insider Activity at Castle Biosciences

In other news, insider Tobin W. Juvenal sold 9,050 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $35.04, for a total value of $317,112.00. Following the sale, the insider directly owned 66,914 shares in the company, valued at $2,344,666.56. The trade was a 11.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 2,546 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $30.68, for a total transaction of $78,111.28. Following the completion of the sale, the insider owned 21,479 shares in the company, valued at approximately $658,975.72. This trade represents a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 169,957 shares of company stock valued at $4,996,708 over the last 90 days. 6.10% of the stock is owned by corporate insiders.

Castle Biosciences Stock Up 0.5%

Shares of CSTL opened at $34.26 on Friday. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -51.91 and a beta of 0.98. Castle Biosciences, Inc. has a 1 year low of $17.72 and a 1 year high of $44.28. The business’s 50 day simple moving average is $26.99 and its 200-day simple moving average is $25.42. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The firm had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. As a group, equities analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.